Drilldown: Medicines

None (2) · Sodium bicarbonate (1)

Ajovy (1) · Emgality (1) · Neut, many generic; OTC oral: Alka-Seltzer (with aspirin/citric acid), baking soda (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Antacids|Antacid]] (1) · [[:Category:Electrolyte_replacements|Electrolyte replacement]] (1)

Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · '"`UNIQ--vote-00000016-QINU`"' Bicarbonate is not benign: high-volume use produces hypernatremia, metabolic alkalosis, hypokalemia, and (in arrest) paradoxical intracellular acidosis'"`UNIQ--ref-00000017-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1)

225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · IV: 1 mEq/kg bolus in arrest indication, then titrated to ABG and clinical status; PO: 325-2000 mg up to QID as antacid (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 4.2%, 7.5%, 8.4% IV (1 mEq/mL at 8.4%); 325, 650 mg oral tablets; bulk powder (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 675 mg/quarter (1) · No fixed maximum; titrated to pH and bicarbonate level; chronic high oral doses cause metabolic alkalosis and volume overload (1)

IV (1) · oral (1) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

IV: hours, dependent on ongoing acid load; oral antacid: ~30 minutes (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)

Not applicable (electrolyte and buffer) (1) · ~27 days (1) · ~31 days (1)

100% (IV); rapidly neutralized by gastric acid (oral) (1) · Not formally established (1) · Not formally established (high SC) (1)

Limited data; avoid (2) · Routine antacid and acidosis correction acceptable (1)

Rx (2) · [[USLegal:Prescription only|Rx-only]] for IV formulations; OTC for oral (1)